Sarwar Alam

1 week ago | pharmacy.biz | Sarwar Alam

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris. From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

1 week ago | pharmacy.biz | Sarwar Alam

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

1 week ago | pharmacy.biz | Sarwar Alam

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters. An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

1 week ago | pharmacy.biz | Sarwar Alam

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technicianThe fund offers £150 per eligible child - for up to three children per household - helping to cover costs such as school uniforms, stationery and travel.

1 week ago | pharmacy.biz | Sarwar Alam

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments. BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".